06:31 AM EDT, 04/15/2026 (MT Newswires) -- ARS Pharmaceuticals ( SPRY ) said Wednesday that Health Canada has approved its neffy 2mg nasal spray for the emergency treatment of anaphylaxis.

The approval covers adults and children weighing at least 30 kilograms, providing patients with a needle-free option, the company said.

The biopharmaceutical company said the nasal spray is expected to be commercially available in Canada in summer 2026.

The company also said it plans to file for approval of neffy 1mg dose for smaller children.